We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Abbott Diagnostics

  Gold Abbott Diagnostics provides medical diagnostic instruments, tests, automation and informatics solutions, including cl... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Highly Sensitive Thyroglobulin Chemiluminescent Microparticle Immunoassay Evaluated

By LabMedica International staff writers
Posted on 20 Jul 2022
Print article
Image: The Alinity I Immunoassay analyzer (Photo courtesy of Abbott)
Image: The Alinity I Immunoassay analyzer (Photo courtesy of Abbott)

Differentiated thyroid cancer (DTC) is the most frequent endocrine malignancy. Standard treatment of DTC is thyroidectomy plus, for high risk cases, radioactive iodine ablation therapy, and pharmacological suppression of TSH.

Thyroglobulin (Tg) measurement is an essential diagnostic element of the follow-up and management of patients with differentiated thyroid cancer (DTC), as the 660 kDa glycoprotein is exclusively produced by benign or well-differentiated malignant thyroid cells. Tg is the matrix for synthesis and storage form of thyroxine (T4) and triiodothyronine (T3) within the thyroid follicles.

Clinical Biochemists at the University Health Network (UHN, Toronto, ON, Canada) participated in a three-center study, Tg values of 447 routine patient samples, characterized for the presence of anti-Tg. Mostly fresh samples from routine Tg requests were used. In addition, frozen samples, and precision and limit of quantitation patient pools and controls were utilized.

Samples were measured on ARCHITECT i2000SR (Abbott, Abbott Park, IL, USA) at three sites and Abbott’s Alinity i analyzer at one site using respective Tg and anti-Tg reagents, calibrators, and controls. For method comparison, samples were measured on a cobas 411 (Roche Diagnostics, Rotkreuz, Switzerland) at all three sites and on UniCel DxI 800 (Beckman Coulter, Brea, CA, USA) at one site using respective reagents, calibrators, and controls. Anti-Tg status was determined using Alinity i anti-Tg assay or ARCHITECT anti-Tg.

Serum Tg measured using with ARCHITECT was compared with the Roche Elecsys Tg II results. In total, 447 patient samples were analyzed for ARCHITECT and Roche with 56 samples positive for anti-Tg (cutoff 4.1 IU/mL). ARCHITECT Tg concentrations were ranging from 0.09 to 486 ng/mL for anti-Tg-negative and 0.09 to 341 ng/mL for anti-Tg-positive samples. Roche Tg values were closely correlated, with a correlation coefficient greater than 0.98 and a slope within 0.9–1.1 for anti-Tg-negative and anti-Tg-positive samples. Limit of quantitation (LoQ) was verified to be less than or equal to 0.1 ng/mL confirming that the Tg assay on ARCHITECT and Alinity was highly sensitive.

The authors concluded that the Abbott Thyroglobulin assay, which is standardized to the human thyroglobulin reference material (CRM-457), demonstrated a high correlation to the Roche and Beckman Tg assays, though good agreement of absolute values was only observed between Abbott and Roche. Strength of correlation and slope were not affected by the presence of anti-Tg indicating that all assays included in the study have a similar susceptibility to anti-Tg. The study was published on July 15, 2022 in the Journal of Clinical Laboratory Analysis.

Related Links:
University Health Network 
Abbott
Roche Diagnostics 
Beckman Coulter 

New
Gold Supplier
Microplate-Strip Washer
Wellwash Versa
New
Gold Supplier
Body Fluid Application
CellaVision Body Fluid Application
New
Gold Supplier
Automated, Random Access Chemistry Analyzer
LIDA 300
New
Gold Supplier
Automated Nucleic Acid Extraction Workstation
SAW-96

Print article

Channels

Molecular Diagnostics

view channel
Image: A new blood test could noninvasively and inexpensively detect colorectal cancer (Photo courtesy of Pexels)

Novel Blood Test Could Detect Early-Onset Colorectal Cancer

Colorectal cancer is the fourth most common cancer, according to the U.S. Centers for Disease Control and Prevention. The rate of colon or rectal cancers in people younger than 50 years old has been on... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.